Related Experiment Video
Updated: Jul 19, 2025
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.4K
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP
Chuandong Geng1, Man-Chao Zhang1, Ganiraju C Manyam2
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Summary
Speckle-type POZ protein (SPOP) mutations in prostate cancer alter STING signaling, creating vulnerabilities. PARP inhibitors can shift this signaling to an antitumor response, improving treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Speckle-type POZ protein (SPOP) plays a role in DNA damage response and genomic stability.
- Somatic heterozygous missense mutations in SPOP are prevalent in prostate cancer (PCa).
- SPOP mutations are linked to treatment response but patient outcomes remain heterogeneous, with limited options for SPOP-mutant castrate-resistant prostate cancer (CRPC).
Purpose of the Study:
- To elucidate the mechanistic links between SPOP mutations, STING signaling, and PARP inhibitor (PARPi) efficacy in prostate cancer.
- To identify novel therapeutic strategies for SPOP-mutant CRPC.
Main Methods:
- In silico analysis of genomic and transcriptomic tumor data.
- Proteomics analysis.
- Genetically modified cell line models and preclinical CRPC models (in vitro and in vivo).
Main Results:
- SPOP mutations correlate with a noncanonical (NC) STING signature in a subset of treatment-refractory CRPC.
- SPOP normally destabilizes STING1; SPOP mutations lead to upregulated NC-STING-NF-κB signaling, promoting tumor growth via the tumor microenvironment.
- PARPi treatment reverses immunosuppressive NC-STING signaling to antitumor canonical cGAS-STING-IFNβ signaling in SPOP-mutant CRPC, inhibiting tumor growth.
Conclusions:
- SPOP critically regulates the balance between immunosuppressive and antitumor signaling downstream of DNA damage-induced STING1 activation in prostate cancer.
- PARPi treatment represents a novel, biomarker-informed strategy to redirect STING signaling towards an antitumor response in SPOP-mutant CRPC.
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K